• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.基于慢病毒载体的树突状细胞疫苗诱导的 HIV-1 Gag 特异性免疫。
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20382-7. doi: 10.1073/pnas.0911742106. Epub 2009 Nov 16.
2
PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.PD-1/PD-L1 阻断可以增强树突状细胞定向慢病毒疫苗引发的 HIV-1 Gag 特异性 T 细胞免疫。
Mol Ther. 2012 Sep;20(9):1800-1809. doi: 10.1038/mt.2012.98. Epub 2012 May 15.
3
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.鼻内接种具有复制能力的仙台病毒载体1型人类免疫缺陷病毒(HIV-1) gag疫苗的安全性和免疫原性的首次人体评估:在初免-加强免疫方案中诱导强效T细胞或抗体反应
J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.
4
Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.基于表达中国HIV-1 B亚型gag基因的DNA、腺病毒和仙台病毒载体的初免-加强-加强策略诱导的强效特异性免疫反应。
Vaccine. 2008 Nov 11;26(48):6124-31. doi: 10.1016/j.vaccine.2008.09.017. Epub 2008 Sep 22.
5
Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.采用腺载体(Gag和Tat)初免/蛋白加强方案及注射粒细胞巨噬细胞集落刺激因子增强针对HIV-1的免疫反应。
Iran J Allergy Asthma Immunol. 2016 Oct;15(5):403-412.
6
An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.基于 HIV 的慢病毒载体作为 HIV 疫苗候选物:免疫原性特征。
Vaccine. 2010 Feb 23;28(8):1952-61. doi: 10.1016/j.vaccine.2009.10.089.
7
Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.表达 HIV-1 Gag 的重组狂犬病病毒疫苗载体感染的树突状细胞具有免疫原性,即使存在载体特异性免疫。
Vaccine. 2010 Dec 10;29(1):130-40. doi: 10.1016/j.vaccine.2010.08.042. Epub 2010 Aug 20.
8
Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.病毒样疫苗对抗 HIV/SIV 与亚优势抗原 T 细胞疫苗具有协同作用。
J Transl Med. 2019 May 24;17(1):175. doi: 10.1186/s12967-019-1924-1.
9
Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.在非人灵长类动物模型中,对营养缺陷型牛分枝杆菌 BCG-VLP 初免-加强 HIV 疫苗候选物产生稳健的免疫应答。
J Virol. 2013 May;87(9):5151-60. doi: 10.1128/JVI.03178-12. Epub 2013 Feb 28.
10
A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.一种靶向树突状细胞的疫苗可在胃肠道内诱导长期的HIV特异性免疫。
Mucosal Immunol. 2016 Sep;9(5):1340-52. doi: 10.1038/mi.2015.133. Epub 2016 Jan 6.

引用本文的文献

1
Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.慢病毒载体:从野生型病毒到高效多功能递送载体
Int J Mol Sci. 2025 Sep 1;26(17):8497. doi: 10.3390/ijms26178497.
2
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.基于病毒载体和病毒样颗粒的传染病疫苗:综述。
Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15.
3
Development of Virus-like Particle Plant-Based Vaccines against Avian H5 and H9 Influenza A Viruses.针对甲型禽流感H5和H9病毒的基于植物的病毒样颗粒疫苗的研发
Vet Sci. 2024 Feb 18;11(2):93. doi: 10.3390/vetsci11020093.
4
An Update on the HIV DNA Vaccine Strategy.HIV DNA疫苗策略的最新进展。
Vaccines (Basel). 2021 Jun 5;9(6):605. doi: 10.3390/vaccines9060605.
5
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus.单次接种 NILV 疫苗可快速持久预防寨卡病毒。
Mol Ther. 2020 Aug 5;28(8):1772-1782. doi: 10.1016/j.ymthe.2020.05.016. Epub 2020 May 20.
6
An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.一种工程化新型慢病毒载体,通过上调 T 细胞中的自噬作用特异性转导树突状细胞,并引发强烈的 HBV 特异性 CTL 反应。
Cell Cycle. 2018;17(10):1220-1234. doi: 10.1080/15384101.2018.1471312. Epub 2018 Jul 18.
7
Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.树突状细胞靶向慢病毒载体免疫采用假转导以及DNA介导的STING和cGAS激活。
Sci Immunol. 2017 Jul 21;2(13). doi: 10.1126/sciimmunol.aal1329.
8
Recent Advances in Lentiviral Vaccines for HIV-1 Infection.用于HIV-1感染的慢病毒疫苗的最新进展
Front Immunol. 2016 Jun 21;7:243. doi: 10.3389/fimmu.2016.00243. eCollection 2016.
9
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.抗原呈递细胞靶向肿瘤疫苗的优缺点。
J Immunol Res. 2015;2015:785634. doi: 10.1155/2015/785634. Epub 2015 Oct 25.
10
Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.生成一个稳定的包装细胞系,产生高滴度 PPT 缺失整合缺陷慢病毒载体。
Mol Ther Methods Clin Dev. 2015 Jul 22;2:15025. doi: 10.1038/mtm.2015.25. eCollection 2015.

本文引用的文献

1
New insights on adenovirus as vaccine vectors.腺病毒作为疫苗载体的新见解。
Mol Ther. 2009 Aug;17(8):1333-9. doi: 10.1038/mt.2009.130. Epub 2009 Jun 9.
2
Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection.中和抗体引发的猴免疫缺陷病毒感染控制中多功能CD4 + T细胞的诱导
J Virol. 2009 Jun;83(11):5514-24. doi: 10.1128/JVI.00145-09. Epub 2009 Mar 18.
3
Dendritic cell-based human immunodeficiency virus vaccine.基于树突状细胞的人类免疫缺陷病毒疫苗。
J Intern Med. 2009 Jan;265(1):138-58. doi: 10.1111/j.1365-2796.2008.02047.x.
4
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.HIV-1疫苗诱导的概念验证性初步研究中的免疫:病例队列分析
Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.
5
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.一种细胞介导免疫HIV-1疫苗的疗效评估(STEP研究):一项双盲、随机、安慰剂对照的概念验证试验。
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
6
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.基于T细胞的疫苗对恒河猴SIV攻击的免疫控制。
Nature. 2009 Jan 1;457(7225):87-91. doi: 10.1038/nature07469. Epub 2008 Nov 9.
7
Challenges in the development of an HIV-1 vaccine.人类免疫缺陷病毒1型疫苗研发中的挑战。
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
8
DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.DNA gag/腺病毒 5 型(Ad5)gag 疫苗和 Ad5 gag/Ad5 gag 疫苗诱导不同的 T 细胞反应谱。
J Virol. 2008 Aug;82(16):8161-71. doi: 10.1128/JVI.00620-08. Epub 2008 Jun 4.
9
Toward an AIDS vaccine.迈向艾滋病疫苗。
Science. 2008 May 9;320(5877):760-4. doi: 10.1126/science.1152622.
10
Engineered lentivector targeting of dendritic cells for in vivo immunization.用于体内免疫的树突状细胞靶向工程化慢病毒载体。
Nat Biotechnol. 2008 Mar;26(3):326-34. doi: 10.1038/nbt1390. Epub 2008 Feb 24.

基于慢病毒载体的树突状细胞疫苗诱导的 HIV-1 Gag 特异性免疫。

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.

机构信息

Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA.

出版信息

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20382-7. doi: 10.1073/pnas.0911742106. Epub 2009 Nov 16.

DOI:10.1073/pnas.0911742106
PMID:19918062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2777969/
Abstract

Lentivectors (LVs) have attracted considerable interest for their potential as a vaccine delivery vehicle. In this study, we evaluate in mice a dendritic cell (DC)-directed LV system encoding the Gag protein of human immunodeficiency virus (HIV) (LV-Gag) as a potential vaccine for inducing an anti-HIV immune response. The DC-directed specificity is achieved through pseudotyping the vector with an engineered Sindbis virus glycoprotein capable of selectively binding to the DC-SIGN protein. A single immunization by this vector induces a durable HIV Gag-specific immune response. We investigated the antigen-specific immunity and T-cell memory generated by a prime/boost vaccine regimen delivered by either successive LV-Gag injections or a DNA prime/LV-Gag boost protocol. We found that both prime/boost regimens significantly enhance cellular and humoral immune responses. Importantly, a heterologous DNA prime/LV-Gag boost regimen results in superior Gag-specific T-cell responses as compared with a DNA prime/adenovector boost immunization. It induces not only a higher magnitude response, as measured by Gag-specific tetramer analysis and intracellular IFN-gamma staining, but also a better quality of response evidenced by a wider mix of cytokines produced by the Gag-specific CD8(+) and CD4(+) T cells. A boosting immunization with LV-Gag also generates T cells reactive to a broader range of Gag-derived epitopes. These results demonstrate that this DC-directed LV immunization is a potent modality for eliciting anti-HIV immune responses.

摘要

慢病毒 (LVs) 因其作为疫苗传递载体的潜力而引起了相当大的关注。在这项研究中,我们在小鼠中评估了一种树突状细胞 (DC) 定向的 LV 系统,该系统编码人类免疫缺陷病毒 (HIV) 的 Gag 蛋白 (LV-Gag),作为诱导抗 HIV 免疫反应的潜在疫苗。通过用能够选择性结合 DC-SIGN 蛋白的工程化辛德毕斯病毒糖蛋白对载体进行假型化,实现了 DC 定向特异性。单次免疫该载体可诱导持久的 HIV Gag 特异性免疫反应。我们研究了由 LV-Gag 连续注射或 DNA 初免/LV-Gag 加强方案进行的初免/加强疫苗方案产生的抗原特异性免疫和 T 细胞记忆。我们发现,两种初免/加强方案均显著增强了细胞和体液免疫反应。重要的是,与 DNA 初免/腺病毒载体加强免疫相比,异源 DNA 初免/LV-Gag 加强方案导致更好的 Gag 特异性 T 细胞反应。它不仅诱导更高幅度的反应,如通过 Gag 特异性四聚体分析和细胞内 IFN-γ染色测量,而且还诱导更好的反应质量,表现为 Gag 特异性 CD8(+) 和 CD4(+) T 细胞产生的细胞因子混合更广泛。用 LV-Gag 进行加强免疫也会产生对更广泛范围的 Gag 衍生表位有反应的 T 细胞。这些结果表明,这种 DC 定向的 LV 免疫是引发抗 HIV 免疫反应的有效方式。